Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model

Alexander W. Scott, Betty Mae Tyler, Byron C. Masi, Urvashi M. Upadhyay, Yoda R. Patta, Rachel Grossman, Luca Basaldella, Robert S. Langer, Henry Brem, Michael J. Cima

Research output: Contribution to journalArticle

Abstract

Controlled-release drug delivery systems are capable of treating debilitating diseases, including cancer. Brain cancer, in particular glioblastoma multiforme (GBM), is an extremely invasive cancer with a dismal prognosis. The use of drugs capable of crossing the blood-brain barrier has shown modest prolongation in patient survival, but not without unsatisfactory systemic, dose-limiting toxicity. Among the reasons for this improvement include a better understanding of the challenges of delivery of effective agents directly to the brain tumor site. The combination of carmustine delivered by biodegradable polyanhydride wafers (Gliadel®), with the systemic alkylating agent, temozolomide, allows much higher effective doses of the drug while minimizing the systemic toxicity. We have previously shown that locally delivering these two drugs leads to further improvement in survival in experimental models. We postulated that microcapsule devices capable of releasing temozolomide would increase the therapeutic capability of this approach. A biocompatible drug delivery microcapsule device for the intracranial delivery of temozolomide is described. Drug release profiles from these microcapsules can be modulated based on the physical chemistry of the drug and the dimensions of the release orifices in these devices. The drug released from the microcapsules in these experiments was the clinically utilized chemotherapeutic agent, temozolomide. In vitro studies were performed in order to test the function, reliability, and drug release kinetics of the devices. The efficacy of the temozolomide-filled microcapsules was tested in an intracranial experimental rodent gliosarcoma model. Immunohistochemical analysis of tissue for evidence of DNA strand breaks via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed. The experimental release curves showed mass flow rates of 36 μg/h for single-orifice devices and an 88 μg/h mass flow rate for multiple-orifice devices loaded with temozolomide. In vivo efficacy results showed that localized intracranial delivery of temozolomide from microcapsule devices was capable of prolonging animal survival and may offer a novel form of treatment for brain tumors.

Original languageEnglish (US)
Pages (from-to)2532-2539
Number of pages8
JournalBiomaterials
Volume32
Issue number10
DOIs
StatePublished - Apr 2011

Fingerprint

temozolomide
Gliosarcoma
Orifices
Drug delivery
Capsules
Brain
Theoretical Models
Equipment and Supplies
Toxicity
Tumors
Flow rate
Pharmaceutical Preparations
Physical chemistry
Brain Neoplasms
Labeling
Assays
Animals
DNA
Therapeutics
Polyanhydrides

Keywords

  • Drug delivery
  • Glioblastoma multiforme
  • Gliosarcoma
  • Intracranial
  • Microcapsule
  • Temozolomide

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Scott, A. W., Tyler, B. M., Masi, B. C., Upadhyay, U. M., Patta, Y. R., Grossman, R., ... Cima, M. J. (2011). Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials, 32(10), 2532-2539. https://doi.org/10.1016/j.biomaterials.2010.12.020

Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. / Scott, Alexander W.; Tyler, Betty Mae; Masi, Byron C.; Upadhyay, Urvashi M.; Patta, Yoda R.; Grossman, Rachel; Basaldella, Luca; Langer, Robert S.; Brem, Henry; Cima, Michael J.

In: Biomaterials, Vol. 32, No. 10, 04.2011, p. 2532-2539.

Research output: Contribution to journalArticle

Scott, AW, Tyler, BM, Masi, BC, Upadhyay, UM, Patta, YR, Grossman, R, Basaldella, L, Langer, RS, Brem, H & Cima, MJ 2011, 'Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model', Biomaterials, vol. 32, no. 10, pp. 2532-2539. https://doi.org/10.1016/j.biomaterials.2010.12.020
Scott, Alexander W. ; Tyler, Betty Mae ; Masi, Byron C. ; Upadhyay, Urvashi M. ; Patta, Yoda R. ; Grossman, Rachel ; Basaldella, Luca ; Langer, Robert S. ; Brem, Henry ; Cima, Michael J. / Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. In: Biomaterials. 2011 ; Vol. 32, No. 10. pp. 2532-2539.
@article{9689963013614a85885223f18172f4bd,
title = "Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model",
abstract = "Controlled-release drug delivery systems are capable of treating debilitating diseases, including cancer. Brain cancer, in particular glioblastoma multiforme (GBM), is an extremely invasive cancer with a dismal prognosis. The use of drugs capable of crossing the blood-brain barrier has shown modest prolongation in patient survival, but not without unsatisfactory systemic, dose-limiting toxicity. Among the reasons for this improvement include a better understanding of the challenges of delivery of effective agents directly to the brain tumor site. The combination of carmustine delivered by biodegradable polyanhydride wafers (Gliadel{\circledR}), with the systemic alkylating agent, temozolomide, allows much higher effective doses of the drug while minimizing the systemic toxicity. We have previously shown that locally delivering these two drugs leads to further improvement in survival in experimental models. We postulated that microcapsule devices capable of releasing temozolomide would increase the therapeutic capability of this approach. A biocompatible drug delivery microcapsule device for the intracranial delivery of temozolomide is described. Drug release profiles from these microcapsules can be modulated based on the physical chemistry of the drug and the dimensions of the release orifices in these devices. The drug released from the microcapsules in these experiments was the clinically utilized chemotherapeutic agent, temozolomide. In vitro studies were performed in order to test the function, reliability, and drug release kinetics of the devices. The efficacy of the temozolomide-filled microcapsules was tested in an intracranial experimental rodent gliosarcoma model. Immunohistochemical analysis of tissue for evidence of DNA strand breaks via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed. The experimental release curves showed mass flow rates of 36 μg/h for single-orifice devices and an 88 μg/h mass flow rate for multiple-orifice devices loaded with temozolomide. In vivo efficacy results showed that localized intracranial delivery of temozolomide from microcapsule devices was capable of prolonging animal survival and may offer a novel form of treatment for brain tumors.",
keywords = "Drug delivery, Glioblastoma multiforme, Gliosarcoma, Intracranial, Microcapsule, Temozolomide",
author = "Scott, {Alexander W.} and Tyler, {Betty Mae} and Masi, {Byron C.} and Upadhyay, {Urvashi M.} and Patta, {Yoda R.} and Rachel Grossman and Luca Basaldella and Langer, {Robert S.} and Henry Brem and Cima, {Michael J.}",
year = "2011",
month = "4",
doi = "10.1016/j.biomaterials.2010.12.020",
language = "English (US)",
volume = "32",
pages = "2532--2539",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model

AU - Scott, Alexander W.

AU - Tyler, Betty Mae

AU - Masi, Byron C.

AU - Upadhyay, Urvashi M.

AU - Patta, Yoda R.

AU - Grossman, Rachel

AU - Basaldella, Luca

AU - Langer, Robert S.

AU - Brem, Henry

AU - Cima, Michael J.

PY - 2011/4

Y1 - 2011/4

N2 - Controlled-release drug delivery systems are capable of treating debilitating diseases, including cancer. Brain cancer, in particular glioblastoma multiforme (GBM), is an extremely invasive cancer with a dismal prognosis. The use of drugs capable of crossing the blood-brain barrier has shown modest prolongation in patient survival, but not without unsatisfactory systemic, dose-limiting toxicity. Among the reasons for this improvement include a better understanding of the challenges of delivery of effective agents directly to the brain tumor site. The combination of carmustine delivered by biodegradable polyanhydride wafers (Gliadel®), with the systemic alkylating agent, temozolomide, allows much higher effective doses of the drug while minimizing the systemic toxicity. We have previously shown that locally delivering these two drugs leads to further improvement in survival in experimental models. We postulated that microcapsule devices capable of releasing temozolomide would increase the therapeutic capability of this approach. A biocompatible drug delivery microcapsule device for the intracranial delivery of temozolomide is described. Drug release profiles from these microcapsules can be modulated based on the physical chemistry of the drug and the dimensions of the release orifices in these devices. The drug released from the microcapsules in these experiments was the clinically utilized chemotherapeutic agent, temozolomide. In vitro studies were performed in order to test the function, reliability, and drug release kinetics of the devices. The efficacy of the temozolomide-filled microcapsules was tested in an intracranial experimental rodent gliosarcoma model. Immunohistochemical analysis of tissue for evidence of DNA strand breaks via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed. The experimental release curves showed mass flow rates of 36 μg/h for single-orifice devices and an 88 μg/h mass flow rate for multiple-orifice devices loaded with temozolomide. In vivo efficacy results showed that localized intracranial delivery of temozolomide from microcapsule devices was capable of prolonging animal survival and may offer a novel form of treatment for brain tumors.

AB - Controlled-release drug delivery systems are capable of treating debilitating diseases, including cancer. Brain cancer, in particular glioblastoma multiforme (GBM), is an extremely invasive cancer with a dismal prognosis. The use of drugs capable of crossing the blood-brain barrier has shown modest prolongation in patient survival, but not without unsatisfactory systemic, dose-limiting toxicity. Among the reasons for this improvement include a better understanding of the challenges of delivery of effective agents directly to the brain tumor site. The combination of carmustine delivered by biodegradable polyanhydride wafers (Gliadel®), with the systemic alkylating agent, temozolomide, allows much higher effective doses of the drug while minimizing the systemic toxicity. We have previously shown that locally delivering these two drugs leads to further improvement in survival in experimental models. We postulated that microcapsule devices capable of releasing temozolomide would increase the therapeutic capability of this approach. A biocompatible drug delivery microcapsule device for the intracranial delivery of temozolomide is described. Drug release profiles from these microcapsules can be modulated based on the physical chemistry of the drug and the dimensions of the release orifices in these devices. The drug released from the microcapsules in these experiments was the clinically utilized chemotherapeutic agent, temozolomide. In vitro studies were performed in order to test the function, reliability, and drug release kinetics of the devices. The efficacy of the temozolomide-filled microcapsules was tested in an intracranial experimental rodent gliosarcoma model. Immunohistochemical analysis of tissue for evidence of DNA strand breaks via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed. The experimental release curves showed mass flow rates of 36 μg/h for single-orifice devices and an 88 μg/h mass flow rate for multiple-orifice devices loaded with temozolomide. In vivo efficacy results showed that localized intracranial delivery of temozolomide from microcapsule devices was capable of prolonging animal survival and may offer a novel form of treatment for brain tumors.

KW - Drug delivery

KW - Glioblastoma multiforme

KW - Gliosarcoma

KW - Intracranial

KW - Microcapsule

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=79251593273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251593273&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.12.020

DO - 10.1016/j.biomaterials.2010.12.020

M3 - Article

C2 - 21220172

AN - SCOPUS:79251593273

VL - 32

SP - 2532

EP - 2539

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 10

ER -